SHORT-TERM (4 WEEKS) SAFETY AND EFFICACY OF TENOFOVIR ALAFENAMIDE (TAF) COMPARED TO TENOFOVIR DISOPROXIL FUMARATE (TDF) AND ENTERCAVIR (ETV) IN TREATMENT-NAIVE ADULT PATIENTS WITH HBV-ACLF FROM SOUTH CHINA

被引：0
|
作者：
Peng, Liang [1 ]
Wu, Lina [1 ]
Zhang, Yeqiong [1 ]
Zhu, Xiang [1 ]
Li, Xuejun [1 ]
Xu, Wenxiong [1 ]
Zhen, Limin [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
492
引用
收藏
页码：311A / 312A
页数：2
相关论文
共 39 条
  • [1] 48 WEEKS SAFETY AND EFFICACY OF TENOFOVIR ALAFENAMIDE COMPARED TO TENOFOVIR DISOPROXIL FUMARATE AND ENTERCAVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS B IN CHINA
    Zhang, Yeqiong
    Xu, Wenxiong
    Wang, Lu
    Wu, Lina
    Li, Jiangguo
    Xie, Chan
    Peng, Liang
    HEPATOLOGY, 2020, 72 : 474A - 475A
  • [2] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Chan, Henry Lik-Yuen
    Buti, Maria
    Flisiak, Robert
    Ryder, Stephen
    Streinu-Cercel, Adrian
    Flaherty, John F.
    Gaggar, Anuj
    Mo, Shuyuan
    Subramanian, G. Mani
    Zoulim, Fabrian
    Andreone, Pietro
    Marcellin, Patrick
    GUT, 2018, 67 : A97 - A97
  • [3] Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)
    Buti, Maria
    Stepanova, Tatjana
    Celen, Mustafa K.
    Flisiak, Robert
    Ryder, Stephen D.
    Streinu-Cercel, Adrian
    Gurel, Selim
    Flaherty, John F.
    Gaggar, Anuj
    Suri, Vithika
    Mo, Shuyuan
    Subramanian, Mani
    Nurmukhametova, Elena
    Zoulim, Fabien
    Andreone, Pietro
    Marcellin, Patrick
    HEPATOLOGY, 2017, 66 : 488A - 488A
  • [4] SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE
    Buti, Maria
    Lampertico, Pietro
    Lim, Young-Suk
    Agarwal, Kosh
    Fung, Scott K.
    Tsang, Owen
    Elkhashab, Magdy
    Kao, Jia-Horng
    Luis Calleja, Jose
    Khalili, Mandana
    Ravendhran, Natarajan
    Tan, Susanna
    Flaherty, John F.
    Gaggar, Anuj
    Lau, Audrey H.
    Wu, George
    Hann, Hie-Won L.
    Pan, Calvin
    Kim, Hyung Joon
    Kennedy, Patrick T. F.
    Chan, Henry Lik Yuen
    HEPATOLOGY, 2019, 70 : 301A - 301A
  • [5] Week 96 Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF) in Older, HIV-Infected Treatment-Naive Adults
    Ward, D.
    Thompson, M.
    Goldstein, D.
    Brinson, C.
    Crofoot, G.
    Kinder, C.
    Ryu, J.
    McNicholl, I.
    Haubrich, R.
    Weinberg, A.
    Sparrow, T. L.
    McCallister, S.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S48 - S48
  • [6] IMPACT OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DURATION ON TENOFOVIR ALAFENAMIDE (TAF) SAFETY PROFILE IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TDF TO TAF
    Chan, Henry Lik Yuen
    Lampertico, Pietro
    Ahn, Sang Hoon
    Fung, Scott K.
    Bae, Ho S.
    Ramji, Alnoor
    Lee, June Sung
    Shafran, Stephen David
    Gordon, Stuart C.
    Phan, Charles G.
    Tan, Susanna
    Flaherty, John F.
    Gaggar, Anuj
    Wu, George
    Suri, Vithika
    Lau, Daryl
    Byun, Kwan Soo
    Agarwal, Kosh
    Lim, Young-Suk
    Buti, Maria
    HEPATOLOGY, 2019, 70 : 287A - 288A
  • [7] IMPACT OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DURATION ON TENOFOVIR ALAFENAMIDE (TAF) SAFETY PROFILE IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TDF TO TAF
    Chan, Henry Lik Yuen
    Lampertico, Pietro
    Ahn, Sang Hoon
    Fung, Scott
    Bae, Ho
    Ramji, Alnoor
    Lee, Jung Sung
    Shafran, Stephen
    Gordon, Stuart
    Phan, Charles
    Tan, Susanna
    Flaherty, John
    Gaggar, Anuj
    Wu, George
    Suri, Vithika
    Lau, Daryl
    Byun, Kwan Soo
    Agarwal, Kosh
    Lim, Young-Suk
    Buti, Maria
    GUT, 2020, 69 : A74 - A75
  • [8] Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B
    Lim, Jihye
    Choi, Won-Mook
    Shim, Ju Hyun
    Lee, Danbi
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Choi, Jonggi
    JOURNAL OF HEPATOLOGY, 2022, 77 : S842 - S842
  • [9] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF)
    Pan, Calvin Q.
    Gane, Edward
    Seto, Wai-Kay
    Janssen, Harry L.
    Caruntu, Florin
    Kim, Hyung Joon
    Abdurakhmanov, Dzhamal
    Nishiguchi, Shuhei
    Bae, Ho
    Mo, Shuyuan
    Suri, Vithika
    Gaggar, Anuj
    Flaherty, John F.
    Kao, Jia-Horng
    Brunetto, Maurizia Rossana
    Buti, Maria
    GASTROENTEROLOGY, 2018, 154 (06) : S1132 - S1133
  • [10] VIROLOGIC, BIOCHEMICAL, AND RENAL OUTCOMES OF TREATMENT-NAIVE PATIENTS WITH SEQUENTIAL THERAPY FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN ROUTINE PRACTICE
    Toyoda, Hidenori
    Trinh, Huy N.
    Leong, Jennifer
    Atsukawa, Masanori
    Watanabe, Tsunamasa
    Chuma, Makoto
    Liu, Joanne
    Yokohama, Keisuke
    Dang, Hansen
    Maeda, Mayumi
    Le, Richard
    Thin, Khin Naing
    Tran, Sally
    Chien, Nicholas
    Takaguchi, Koichi
    Fukunishi, Shinya
    Yasuda, Satoshi
    Cheung, Ramsey
    Nguyen, Mindie H.
    HEPATOLOGY, 2020, 72 : 498A - 499A
1234